Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa (HemaSphere, 2024)

(untitled) - Ryou, H; Sirinukunwattana, K; Wood, R; Aberdeen, A; Rittscher, J; Weinberg, OK; Hasserjian, R; Pozdnyakova, O; Peale, F; Higgins, B; Lundberg, P; Trunzer, K; et al.